Kobo Biotech (BOM:531541) LT-Debt-to-Total-Asset: 0.44 (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531541 Kobo Biotech Ltd BOM:531541
13 GF Score
Price ₹8.23
View Full Analysis

What is Kobo Biotech LT-Debt-to-Total-Asset?

Kobo Biotech BOM:531541 -1.91% 13 LT-Debt-to-Total-Asset is 0.44 as of Mar. 2025. GuruFocus rates BOM:531541 with a GF Score™ of 13/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Kobo Biotech's long-term debt to total assests ratio for the quarter that ended in Mar. 2025 was 0.44.

Kobo Biotech's long-term debt to total assets ratio stayed the same from Sep. 2023 (0.44) to Mar. 2025 (0.44).

Kobo Biotech  (BOM:531541) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Kobo Biotech LT-Debt-to-Total-Asset Related Terms

Kobo Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Kobo Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kobo Biotech LT-Debt-to-Total-Asset Chart

Kobo Biotech Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.42 0.43 0.44 0.44

Kobo Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Mar25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.00 0.44 0.00 0.44
BOM:531541
13GF Score
Kobo Biotech Ltd BOM:531541
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kobo Biotech LT-Debt-to-Total-Asset Calculation

Kobo Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )/Total Assets (A: Mar. 2025 )
=317.14/715.901
=

Kobo Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (Q: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )/Total Assets (Q: Mar. 2025 )
=317.14/715.901
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.44 mean?
Kobo Biotech (BOM:531541) has a LT-Debt-to-Total-Asset of 0.44 as of Mar. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Kobo Biotech and its competitors.
Is Kobo Biotech's LT-Debt-to-Total-Asset too high?
Kobo Biotech's current LT-Debt-to-Total-Asset is 0.44. Overall, Kobo Biotech has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Kobo Biotech's LT-Debt-to-Total-Asset compare to ZTS?
Kobo Biotech's LT-Debt-to-Total-Asset of 0.44 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Kobo Biotech and its competitors. Kobo Biotech's current LT-Debt-to-Total-Asset is 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobo Biotech stock overvalued right now?
Kobo Biotech (BOM:531541) has a current LT-Debt-to-Total-Asset of 0.44. The current LT-Debt-to-Total-Asset is 0.44. Kobo Biotech's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Kobo Biotech (BOM:531541), the current LT-Debt-to-Total-Asset is 0.44 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kobo Biotech Business Description

Address Saki Vihar Road, Unit 104, HYDE Park, Opposite Ansa Industrial Estate, Andheri (East), Mumbai, MH, IND, 400 072
Kobo Biotech Ltd is a pharmaceutical company. Its business comprises the manufacturing and sale of APIs (Active Pharmaceutical Ingredients) based on fermentation technology and Intermediates to pharmaceutical companies.
13GF Score

Get the complete analysis for BOM:531541

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8.23
Price